Clinical trial
A Phase 1 Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors
NCT01608867 is registered in ClinicalTrials.gov with OncoMed Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 30, 2012
- Completion date
- June 30, 2017
- Enrollment
- 26 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumors